Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome

Trial ID or NCT#

NCT01203358

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this study is to compare the efficacy of two surfactants, Exosurf Neonatal (Burroughs Wellcome Co.) and Survanta (Ross Laboratories), for the treatment of neonatal respiratory distress syndrome.

Official Title

Efficacy and Safety of Exosurf Neonatal and Survanta for the Treatment of Respiratory Distress Syndrome

Eligibility Criteria

Ages Eligible for Study: Younger than 6 Hours
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Newborn infants weighing 501 to 1500 gm with respiratory distress syndrome were receiving assisted ventilation with 30% oxygen or more
Exclusion Criteria:
  1. - Less than 6 hours of age
View All Criteria
Show Less

Investigator(s)

David K. Stevenson, M.D.

View on ClinicalTrials.gov